Gilead Sciences, Inc., Terumo Medical Corporation, and Getinge AB were dominating the Europe Acute Respiratory Distress Syndrome (ARDS) Market in 2021

Europe Acute Respiratory Distress Syndrome (ARDS) Market is expected to grow with a CAGR of 9.5% in the forecast period of 2022 to 2029. The years considered for the study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/europe-acute-respiratory-distress-syndrome-ards-market

Europe acute respiratory distress syndrome (ARDS) market is a highly consolidated market, which includes more key players. The market has witnessed increased strategic developments owing to a favorable market scenario.    

The major players dealing in Europe acute respiratory distress syndrome (ARDS) market are introducing a strong range of products provider along with launching new products and adopting strategic initiatives such as acquisition, and agreement into the market. This helped companies to maximize sales with an enhanced product portfolio.

For instance,

• In May 2021, Medtronic launched the SonarMed airway monitoring system. The system utilizes acoustic technology to check for endotracheal tube obstruction. This has helped the company to increase its product portfolio.

Gilead Sciences Inc. is the dominating player in the Europe acute respiratory distress syndrome (ARDS) market. The other key players existing in the market include Terumo Medical Corporation, Getinge AB., LivaNova PLC, Medtronic, ResMed, Fisher & Paykel Healthcare Limited., F. Hoffmann-La Roche Ltd, Smiths Medical (part of ICU Medical, Inc.), Drägerwerk AG & Co. KGaA, Fresenius SE & Co. KGaA, Hamilton Medical, Pfizer Inc., EUROSETS, Armstrong Medical, nice Neotech Medical Systems Pvt. Ltd., and Besmed Health Business Corp, among others.

Gilead Sciences Inc.

The company focuses on providing and producing antiviral medications, and therapeutics for life-threatening diseases associated with lung injuries and infections. The company also provides medications related to the inflammations associated with ARDS.

For instance,

• In July 2020, Gilead Sciences Inc. initiated clinical testing of an Inhaled Solution of Remdesivir for Potential Outpatient Treatment of COVID-19. This testing helped the company enhance its antiviral product portfolio, thereby strengthening its footprints over the market.

Terumo Medical Corporation

Terumo Medical Corporation was founded in 1921 headquartered in Japan. The company focuses on providing a large portfolio of medical products associated with various clinical practices such as cardiovascular, general hospitals, and blood cell technologies. The company also provides mechanical ventilations, which are needed for lung injury-related diseases.

For instance,

• In April 2020, Terumo Corporation doubled the extracorporeal membrane oxygenation ECMO Production and Supply. ECMO consists of an oxygenator and centrifugal pump, which is used for patients with severe respiratory failure. This has helped the company to increase its market growth in the market.

Getinge AB

The company focuses on providing hospitals and life sciences institutions with various medical products. The company produces mechanical ventilation, which is an absolute necessity for patients who are infected with lung infections associated with ARDS. Hence the company is adding new product features to enhance their quality.

For instance,

• In October 2020, Getinge AB added new features in mechanical ventilation called NAVA- Neurally Adjusted Ventilatory Assist. NAVA can help all types of patients breathe, from tiny premature babies weighing a few hundred grams to frail older patients. This has helped the company to increase its revenue in the market.